Topic
Moderta
Moderna skin cancer vaccine trial shows promise in preventing recurrence
A phase 3 clinical trial evaluating Moderna and Merck's personalized mRNA skin cancer vaccine has met its primary goals in delaying recurrence.
A phase 3 clinical trial evaluating Moderna and Merck's personalized mRNA skin cancer vaccine has met its primary goals in delaying recurrence.